In the announcement, the Italian Ministry of Health said scientific research results showed that the AstraZeneca vaccine could provide “substantial protection” even to people over 65 years of age.
Before that, on March 5, the AstraZeneca vaccine was also licensed by Denmark for use in people over 65 years old. Director of the Danish Health Service Bolette Soborg said the study results in Scotland (UK) showed that AstraZeneca’s vaccine significantly reduced the risk of hospitalization of patients with COVID-19 and in elderly patients. This result has been confirmed on a large scale, she added.
Results of a preliminary study published on March 3 also showed that the COVID-19 preventive vaccine jointly developed by AstraZeneca and Oxford University is effective in preventing severe illness in the elderly up to more than 80. % after 1 injection. The above research results continue to supplement evidence that AstraZeneca’s vaccine is safe and effective for the elderly.
* On the same day of March 8, New Zealand Prime Minister Jacinda Ardern announced that the country had secured a sufficient supply of Pfizer’s COVID-19 vaccine for all people in need.
According to the Vietnam News Agency in Oceania, Prime Minister Ardern said the New Zealand government had just reached an agreement to have an additional 8.5 million doses of Pfizer’s vaccine by the middle of this year in addition to the 1.5 million doses of Pfizer’s vaccine. bought, enough to inject 4.25 million out of 5 million people in this country, with each person injecting two doses. Ms. Ardern asserted that the agreement would take New Zealand one step closer to avoiding the introduction of pandemic control restrictions.
Last month, New Zealand launched a nationwide vaccination campaign and is expected to complete a full immunization by the end of this year.
To date, New Zealand has been one of the most successful countries in responding to the COVID-19 pandemic, with just over 2,000 cases and 26 deaths, thanks to its strict border controls, and traceability system. quick track and short-term immediate blockade.